{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:13:23Z","timestamp":1783196003652,"version":"3.54.6"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,10]]},"DOI":"10.7759\/cureus.75471","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T16:22:44Z","timestamp":1733847764000},"source":"Crossref","is-referenced-by-count":3,"title":["Current Treatment Paradigm and Approach to Advanced Hepatocellular Carcinoma"],"prefix":"10.7759","author":[{"given":"John","family":"Patresan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Chandrasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griffin","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3182872f29","article-title":"Epidemiology of hepatocellular carcinoma: consider the population","volume":"47 Suppl","author":"Mittal S","year":"2013","unstructured":"Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013, 47 Suppl:S2-6. 10.1097\/MCG.0b013e3182872f29","journal-title":"J Clin Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2017.03","article-title":"Management of advanced hepatocellular carcinoma: review of current and potential therapies","volume":"3","author":"Gomaa A","year":"2017","unstructured":"Gomaa A, Waked I. Management of advanced hepatocellular carcinoma: review of current and potential therapies. Hepatoma Res. 2017, 3:112-22. 10.20517\/2394-5079.2017.03","journal-title":"Hepatoma Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study","volume":"35","author":"Park JW","year":"2015","unstructured":"Park JW, Chen M, Colombo M, et al.. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int. 2015, 35:2155-66. 10.1111\/liv.12818","journal-title":"Liver Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290145","article-title":"Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials","volume":"29","author":"Llovet JM","year":"1999","unstructured":"Llovet JM, Bustamante J, Castells A, et al.. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999, 29:62-7. 10.1002\/hep.510290145","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner A","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018, 391:1301-14. 10.1016\/S0140-6736(18)30010-2","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.21037\/tgh.2019.01.02","article-title":"Treatment strategies for locally advanced hepatocellular carcinoma","volume":"4","author":"Fernandes ES","year":"2019","unstructured":"Fernandes ES, Rodrigues PD, \u00c1lvares-da-Silva MR, Scaffaro LA, Farenzena M, Teixeira UF, Waechter FL. Treatment strategies for locally advanced hepatocellular carcinoma. Transl Gastroenterol Hepatol. 2019, 4:12. 10.21037\/tgh.2019.01.02","journal-title":"Transl Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro V","year":"1996","unstructured":"Mazzaferro V, Regalia E, Doci R, et al.. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996, 334:693-9. 10.1056\/NEJM199603143341104","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28643","article-title":"The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study","volume":"64","author":"Sapisochin G","year":"2016","unstructured":"Sapisochin G, Goldaracena N, Laurence JM, et al.. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology. 2016, 64:2077-88. 10.1002\/hep.28643","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i4.649","article-title":"Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation","volume":"7","author":"Guerrero-Misas M","year":"2015","unstructured":"Guerrero-Misas M, Rodr\u00edguez-Per\u00e1lvarez M, De la Mata M. Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol. 2015, 7:649-61. 10.4254\/wjh.v7.i4.649","journal-title":"World J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao FY","year":"2001","unstructured":"Yao FY, Ferrell L, Bass NM, et al.. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001, 33:1394-403. 10.1053\/jhep.2001.24563","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/253517","article-title":"Milan criteria and UCSF criteria: a preliminary comparative study of liver transplantation outcomes in the United States","volume":"2012","author":"Patel SS","year":"2012","unstructured":"Patel SS, Arrington AK, McKenzie S, et al.. Milan criteria and UCSF criteria: a preliminary comparative study of liver transplantation outcomes in the United States. Int J Hepatol. 2012, 2012:253517. 10.1155\/2012\/253517","journal-title":"Int J Hepatol"},{"key":"ref13","article-title":"Risk factors for fatal recurrence of hepatocellular carcinoma and their role in selecting candidates for liver transplantation","volume":"7","author":"Zou WL","year":"2008","unstructured":"Zou WL, Zang YJ, Chen XG, Shen XY. Risk factors for fatal recurrence of hepatocellular carcinoma and their role in selecting candidates for liver transplantation. Hepatobiliary Pancreat Dis Int. 2008, 7:145-51.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro V","year":"2009","unstructured":"Mazzaferro V, Llovet JM, Miceli R, et al.. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009, 10:35-43. 10.1016\/S1470-2045(08)70284-5","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i15.4141","article-title":"Staging systems of hepatocellular carcinoma: a review of literature","volume":"20","author":"Maida M","year":"2014","unstructured":"Maida M, Orlando E, Camm\u00e0 C, Cabibbo G. Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol. 2014, 20:4141-50. 10.3748\/wjg.v20.i15.4141","journal-title":"World J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061465","article-title":"Treatment strategies for hepatocellular carcinoma \u207b a multidisciplinary approach","volume":"20","author":"Lurje I","year":"2019","unstructured":"Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment strategies for hepatocellular carcinoma \u207b a multidisciplinary approach. Int J Mol Sci. 2019, 20:20. 10.3390\/ijms20061465","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.gassur.2005.09.008","article-title":"Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: model of end-stage liver disease (MELD) score predicts perioperative mortality","volume":"9","author":"Teh SH","year":"2005","unstructured":"Teh SH, Christein J, Donohue J, et al.. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: model of end-stage liver disease (MELD) score predicts perioperative mortality. J Gastrointest Surg. 2005, 9:1207-15. 10.1016\/j.gassur.2005.09.008","journal-title":"J Gastrointest Surg"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1159\/000335713","article-title":"How much remnant is enough in liver resection?","volume":"29","author":"Guglielmi A","year":"2012","unstructured":"Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Iacono C. How much remnant is enough in liver resection?. Dig Surg. 2012, 29:6-17. 10.1159\/000335713","journal-title":"Dig Surg"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2450-z","article-title":"A comprehensive meta-regression analysis on outcome of anatomic resection versus nonanatomic resection for hepatocellular carcinoma","volume":"19","author":"Cucchetti A","year":"2012","unstructured":"Cucchetti A, Cescon M, Ercolani G, Bigonzi E, Torzilli G, Pinna AD. A comprehensive meta-regression analysis on outcome of anatomic resection versus nonanatomic resection for hepatocellular carcinoma. Ann Surg Oncol. 2012, 19:3697-705. 10.1245\/s10434-012-2450-z","journal-title":"Ann Surg Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-871198","article-title":"Resection and liver transplantation for hepatocellular carcinoma","volume":"25","author":"Llovet JM","year":"2005","unstructured":"Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005, 25:181-200. 10.1055\/s-2005-871198","journal-title":"Semin Liver Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03853.x","article-title":"Are patients with Child's A cirrhosis and hepatocellular carcinoma appropriate candidates for liver transplantation?","volume":"12","author":"Berry K","year":"2012","unstructured":"Berry K, Ioannou GN. Are patients with Child's A cirrhosis and hepatocellular carcinoma appropriate candidates for liver transplantation?. Am J Transplant. 2012, 12:706-17. 10.1111\/j.1600-6143.2011.03853.x","journal-title":"Am J Transplant"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.091","article-title":"Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma","volume":"134","author":"Ishizawa T","year":"2008","unstructured":"Ishizawa T, Hasegawa K, Aoki T, et al.. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008, 134:1908-16. 10.1053\/j.gastro.2008.02.091","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra065156","article-title":"Strategies for safer liver surgery and partial liver transplantation","volume":"356","author":"Clavien PA","year":"2007","unstructured":"Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med. 2007, 356:1545-59. 10.1056\/NEJMra065156","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.037","article-title":"Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study","volume":"62","author":"Vitale A","year":"2015","unstructured":"Vitale A, Burra P, Frigo AC, et al.. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. J Hepatol. 2015, 62:617-24. 10.1016\/j.jhep.2014.10.037","journal-title":"J Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.03.012","article-title":"Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT","volume":"61","author":"Yin L","year":"2014","unstructured":"Yin L, Li H, Li AJ, et al.. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol. 2014, 61:82-8. 10.1016\/j.jhep.2014.03.012","journal-title":"J Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2011.06917.x","article-title":"Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases","volume":"27","author":"Jung SM","year":"2012","unstructured":"Jung SM, Jang JW, You CR, et al.. Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases. J Gastroenterol Hepatol. 2012, 27:684-9. 10.1111\/j.1440-1746.2011.06917.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.10081634","article-title":"Principles of and advances in percutaneous ablation","volume":"258","author":"Ahmed M","year":"2011","unstructured":"Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology. 2011, 258:351-69. 10.1148\/radiol.10081634","journal-title":"Radiology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21933","article-title":"Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?","volume":"47","author":"Livraghi T","year":"2008","unstructured":"Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, Rossi S. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?. Hepatology. 2008, 47:82-9. 10.1002\/hep.21933","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2005.06.011","article-title":"Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis","volume":"12","author":"Raut CP","year":"2005","unstructured":"Raut CP, Izzo F, Marra P, et al.. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol. 2005, 12:616-28. 10.1245\/ASO.2005.06.011","journal-title":"Ann Surg Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000580","article-title":"Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model","volume":"94","author":"Pillai K","year":"2015","unstructured":"Pillai K, Akhter J, Chua TC, Shehata M, Alzahrani N, Al-Alem I, Morris DL. Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model. Medicine (Baltimore). 2015, 94:580. 10.1097\/MD.0000000000000580","journal-title":"Medicine (Baltimore)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet JM","year":"1999","unstructured":"Llovet JM, Br\u00fa C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999, 19:329-38. 10.1055\/s-2007-1007122","journal-title":"Semin Liver Dis"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo CM","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK, et al.. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002, 35:1164-71. 10.1053\/jhep.2002.33156","journal-title":"Hepatology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet JM","year":"2002","unstructured":"Llovet JM, Real MI, Montana X, et al.. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002, 359:1734-9. 10.1016\/S0140-6736(02)08649-X","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505113321903","article-title":"A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma","volume":"332","year":"1995","unstructured":"A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 1995, 332.1256-61. 10.1056\/NEJM199505113321903","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318210ff17","article-title":"Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction","volume":"45","author":"Hsin IF","year":"2011","unstructured":"Hsin IF, Hsu CY, Huang HC, et al.. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction. J Clin Gastroenterol. 2011, 45:556-62. 10.1097\/MCG.0b013e318210ff17","journal-title":"J Clin Gastroenterol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/01.RVI.0000233785.75257.9A","article-title":"Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations","volume":"17","author":"Salem R","year":"2006","unstructured":"Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol. 2006, 17:1251-78. 10.1097\/01.RVI.0000233785.75257.9A","journal-title":"J Vasc Interv Radiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29691","article-title":"Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience","volume":"68","author":"Salem R","year":"2018","unstructured":"Salem R, Gabr A, Riaz A, et al.. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology. 2018, 68:1429-40. 10.1002\/hep.29691","journal-title":"Hepatology"},{"key":"ref38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2017.12.026","article-title":"Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion","volume":"68","author":"Spreafico C","year":"2018","unstructured":"Spreafico C, Sposito C, Vaiani M, et al.. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol. 2018, 68:724-32.","journal-title":"J Hepatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain V","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, et al.. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017, 18:1624-36. 10.1016\/S1470-2045(17)30683-6","journal-title":"Lancet Oncol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0892","article-title":"Sirvenib: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow PK","year":"2018","unstructured":"Chow PK, Gandhi M, Tan SB, et al.. Sirvenib: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018, 36:1913-21. 10.1200\/JCO.2017.76.0892","journal-title":"J Clin Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.466","article-title":"Targeted therapy for hepatocellular carcinoma: novel agents on the horizon","volume":"3","author":"Cervello M","year":"2012","unstructured":"Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget. 2012, 3:236-60. 10.18632\/oncotarget.466","journal-title":"Oncotarget"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma","volume":"24","author":"Abou-Alfa GK","year":"2006","unstructured":"Abou-Alfa GK, Schwartz L, Ricci S, et al.. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006, 24:4293-300. 10.1200\/JCO.2005.01.3441","journal-title":"J Clin Oncol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet JM","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al.. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008, 359:378-90. 10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng AL","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, et al.. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10:25-34. 10.1016\/S1470-2045(08)70285-7","journal-title":"Lancet Oncol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060841","article-title":"Current treatment landscape for advanced hepatocellular carcinoma: patient outcomes and the impact on quality of life","volume":"11","author":"Li D","year":"2019","unstructured":"Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current treatment landscape for advanced hepatocellular carcinoma: patient outcomes and the impact on quality of life. Cancers (Basel). 2019, 11:841. 10.3390\/cancers11060841","journal-title":"Cancers (Basel)"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0143","article-title":"Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib","volume":"15","author":"Vincenzi B","year":"2010","unstructured":"Vincenzi B, Santini D, Russo A, et al.. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010, 15:85-92. 10.1634\/theoncologist.2009-0143","journal-title":"Oncologist"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","unstructured":"EASL clinical practice guidelines. management of hepatocellular carcinoma. J Hepatol. 2018, 69:182-236. 10.1016\/j.jhep.2018.03.019","journal-title":"J Hepatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12352","article-title":"GIDEON (global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib): second interim analysis","volume":"68","author":"Lencioni R","year":"2014","unstructured":"Lencioni R, Kudo M, Ye SL, et al.. GIDEON (global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib): second interim analysis. Int J Clin Pract. 2014, 68:609-17. 10.1111\/ijcp.12352","journal-title":"Int J Clin Pract"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26586","article-title":"Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design","volume":"58","author":"Reig M","year":"2013","unstructured":"Reig M, Rimola J, Torres F, et al.. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology. 2013, 58:2023-31. 10.1002\/hep.26586","journal-title":"Hepatology"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo M","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al.. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018, 391:1163-73. 10.1016\/S0140-6736(18)30207-1","journal-title":"Lancet"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-019-01642-1","article-title":"REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset","volume":"55","author":"Yamashita T","year":"2020","unstructured":"Yamashita T, Kudo M, Ikeda K, et al.. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020, 55:113-22. 10.1007\/s00535-019-01642-1","journal-title":"J Gastroenterol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/cld.782","article-title":"Treatment for advanced hepatocellular carcinoma: current standard and the future","volume":"13","author":"Likhitsup A","year":"2019","unstructured":"Likhitsup A, Razumilava N, Parikh ND. Treatment for advanced hepatocellular carcinoma: current standard and the future. Clin Liver Dis (Hoboken). 2019, 13:13-9. 10.1002\/cld.782","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.24543.1","article-title":"Hepatocellular carcinoma: recent advances and emerging medical therapies","volume":"9","author":"Ko KL","year":"2020","unstructured":"Ko KL, Mak LY, Cheung KS, Yuen MF. Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Res. 2020, 9:620. 10.12688\/f1000research.24543.1","journal-title":"F1000Res"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28358","article-title":"PD-1\/PD-L1 pathway: basic biology and role in cancer immunotherapy","volume":"234","author":"Salmaninejad A","year":"2019","unstructured":"Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M, Pasdar A, Sahebkar A. PD-1\/PD-L1 pathway: basic biology and role in cancer immunotherapy. J Cell Physiol. 2019, 234:16824-37. 10.1002\/jcp.28358","journal-title":"J Cell Physiol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder EI","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016, 39:98-106. 10.1097\/COC.0000000000000239","journal-title":"Am J Clin Oncol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry AB","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, et al.. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017, 389:2492-502. 10.1016\/S0140-6736(17)31046-2","journal-title":"Lancet"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.4_suppl.226","article-title":"Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): the CheckMate 040 study","volume":"35","author":"El-Khoueiry AB","year":"2017","unstructured":"El-Khoueiry AB, Trojan J, Meyer T, et al.. Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): the CheckMate 040 study. J Clin Oncol. 2017, 35:10.1200\/JCO.2017.35.4_suppl.226","journal-title":"J Clin Oncol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.029","article-title":"CheckMate459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)","volume":"30","author":"Yau T","year":"2019","unstructured":"Yau T, Park JW, Finn RS, et al.. CheckMate459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019, 30:874-5. 10.1093\/annonc\/mdz394.029","journal-title":"Ann Oncol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu AX","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, et al.. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018, 19:940-52. 10.1016\/S1470-2045(18)30351-6","journal-title":"Lancet Oncol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in Keynote-240: a randomized, double-blind, Phase III trial","volume":"38","author":"Finn RS","year":"2020","unstructured":"Finn RS, Ryoo BY, Merle P, et al.. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in Keynote-240: a randomized, double-blind, Phase III trial. J Clin Oncol. 2020, 38:193-202. 10.1200\/JCO.19.01307","journal-title":"J Clin Oncol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4012","article-title":"Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040","volume":"37","author":"Yau T","year":"2019","unstructured":"Yau T, Kang YK, Kim TY, et al.. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040. J Clin Oncol. 2019, 37:4012. 10.1200\/JCO.2019.37.15_suppl.4012","journal-title":"J Clin Oncol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn RS","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al.. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020, 382:1894-905. 10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa GK","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, et al.. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022, 1:2100070. 10.1056\/EVIDoa2100070","journal-title":"NEJM Evid"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa GK","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, et al.. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018, 379:54-63. 10.1056\/NEJMoa1717002","journal-title":"N Engl J Med"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix J","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al.. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017, 389:56-66. 10.1016\/S0140-6736(16)32453-9","journal-title":"Lancet"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu AX","year":"2015","unstructured":"Zhu AX, Park JO, Ryoo BY, et al.. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015, 16:859-70. 10.1016\/S1470-2045(15)00050-9","journal-title":"Lancet Oncol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.02.018","article-title":"UNOS down-staging criteria for liver transplantation of hepatocellular carcinoma: systematic review and meta-analysis of 25 studies","volume":"21","author":"Tan DJ","year":"2023","unstructured":"Tan DJ, Lim WH, Yong JN, et al.. UNOS down-staging criteria for liver transplantation of hepatocellular carcinoma: systematic review and meta-analysis of 25 studies. Clin Gastroenterol Hepatol. 2023, 21:1475-84. 10.1016\/j.cgh.2022.02.018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2020.00037","article-title":"Hepatocellular carcinoma: downstaging to liver transplantation as curative therapy","volume":"9","author":"Frankul L","year":"2021","unstructured":"Frankul L, Frenette C. Hepatocellular carcinoma: downstaging to liver transplantation as curative therapy. J Clin Transl Hepatol. 2021, 9:220-6. 10.14218\/JCTH.2020.00037","journal-title":"J Clin Transl Hepatol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2017.5","article-title":"New knowledge of the mechanisms of sorafenib resistance in liver cancer","volume":"38","author":"Zhu YJ","year":"2017","unstructured":"Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017, 38:614-22. 10.1038\/aps.2017.5","journal-title":"Acta Pharmacol Sin"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/312660-current-treatment-paradigm-and-approach-to-advanced-hepatocellular-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T16:22:50Z","timestamp":1733847770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/312660-current-treatment-paradigm-and-approach-to-advanced-hepatocellular-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":69,"URL":"https:\/\/doi.org\/10.7759\/cureus.75471","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,10]]}}}